Navigation Links
European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report
Date:12/1/2008

EXTON, Pa., Dec. 1 /PRNewswire/ -- BioTrends Research Group, Inc. released its third TreatmentTrends(TM): European Nephrology Report. This report runs parallel to two ongoing studies BioTrends conducts -- TreatmentTrends(TM): US and Canadian Nephrology. The report is based on the results of an on-line survey completed by 200 Nephrologists from the UK, Germany, France, Italy, and Spain. The focus is on the management of renal anemia and hyperphosphatemia.

In the ESA market, Amgen's Aranesp is the market share leader in both dialysis and CKD settings and is perceived to have numerous advantages compared to other ESAs. While the use of biosimilar ESAs did increase in the past six months, this was primarily driven by uptake in the German dialysis market. Almost half of the Nephrologists indicate a high concern with the quality of biosimilar ESAs and there appears to be ambivalence about this class of drugs -- only 20% of Nephrologists agree that they have a good understanding of the differences between biosimilar ESAs and their reference brands. Projected ESA share growth is most favorable for Roche's Mircera, particularly in France and Spain, with the greatest share loss coming from Roche's NeoRecormon. Although Aranesp is expected to see share decreases in almost all markets, Nephrologists project Aranesp will maintain its market leader position in both dialysis and CKD.

In general, IV iron is reserved for patients on hemodialysis with about 65% of those treated receiving a consistent maintenance dose. The use of oral iron is more commonplace than the use of IV iron among CKD patients, but many CKD patients do not receive any iron therapy. Venofer and Ferrlecit are the most familiar brands to Nephrologists with market share varying by country. Newcomer Ferinject (ferric carboxymaltose) has yet to make in-roads with 84% of Nephrologists reporting no experience with the drug.

European Nephrologists rated new agents for hyperphosphatemia as one of the greatest unmet needs for their patients and report that at any given time more than one-third of their dialysis patients are above the target level for phosphorus. Calcium based phosphate binders are the most frequently prescribed binders in both dialysis and CKD, however, there is a high prevalence of combination binder therapy typically involving a calcium based agent combined with Genzyme's Renagel. Future share projections appear to favor Shire's Fosrenol which could be due in part to the diminishing concern with lanthanum absorption.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Kline Study: Better Brushing Habits Boost European Oral Care Sales
5. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
6. European Centre for Modern Drug Discovery Established in Hamburg
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
9. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
10. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Global ... treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols and ... from around the world. , The new GSCG clinic is headed by ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal Inc., ... proprietary NeXosome® technology for early warning of adverse ... most recent study by Dr. Thomas McElrath ... Society for Maternal Fetal Medicine,s (SMFM) annual meeting held ... th , 2016.  The presentation reported initial positive ...
(Date:2/10/2016)... 10, 2016  Allergan plc (NYSE: AGN ) ... Brent Saunders , Allergan,s CEO and President, will be ... session at the RBC Capital Markets Healthcare Conference on ... The New York Palace Hotel in New ... live and can be accessed on Allergan,s Investor Relations ...
(Date:2/10/2016)... ... ... LATHAM, NEW YORK... Marktech Optoelectronics will feature their new high-speed InGaAs ... Moscone Center from February 16-18, 2016, and at the healthcare-focused BiOS Expo on February ... standard packages feature a TO-46 metal can with active areas of 1.0mm and 1.5mm ...
Breaking Biology Technology:
(Date:1/13/2016)... 2016 --> ... market report titled - Biometric Sensors Market - Global Industry ... 2023. According to the report, the global biometric sensors market was valued ... reach US$1,625.8 mn by 2023, expanding at a CAGR ... volume, the biometric sensors market is expected to reach ...
(Date:1/11/2016)... Jan. 11, 2016 Synaptics Incorporated (NASDAQ: ... today announced that its ClearPad ® TouchView ™ ... won two separate categories in the 8 th ... Best Technology Breakthrough. The Synaptics ® TDDI solution ... supply chain, thinner devices, brighter displays and borderless designs. ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016   ... diagnostic products, today announced the closing of a $9 million ... Proceeds from the financing will be used to accelerate the ... for detecting early-stage pressure ulcers. United ... receiving CE Mark approval. The device,s introduction has been met ...
Breaking Biology News(10 mins):